Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

To fight off compounding pharmacies, Eli Lilly wants access to medical records of patients who used copycat products.

Eli Lilly & Co. closed $48.10 short of its 52-week high ($972.53), which the company achieved on August 22nd.

BioAge Labs stock rose Thursday on the company's upsized IPO — reflecting enthusiasm for its approach to obesity treatments.

An investigation, published in the journal The BMJ, found that the newly U.S. Food & Drug Administration-approved donanemab is linked ...

Eli Lilly's long-term growth prospects are strong with improved supply, new growth opportunities, and competitive positioning ...

The letter is the latest sign that the battle between the brand-name drug manufacturers and the companies that make and sell ...

With a market capitalization of over $800 billion, Eli Lilly (NYSE: LLY) is the largest pharmaceutical company in the world.

Eli Lilly's valuation is a critical concern, but its robust execution has improved its ability to actualize its high-growth ...

Eli Lilly has received approval in Japan for Kisunla (donanemab-azbt) to treat early symptomatic Alzheimer's disease.

This is thanks to Lilly's dominance in the billion-dollar weight loss drug market. Lilly's Mounjaro and Zepbound have helped ...

The prospects of the latter two companies looked better following the European pharmaceutical's new clinical trial readout.